Tango Therapeutics, founded in Cambridge, United States, is a biotechnology company dedicated to discovering and developing novel medicines that target cancer vulnerabilities. The company's core mission is to deliver transformational new therapies for cancer patients by leveraging the principle of synthetic lethality. Tango Therapeutics focuses on genetically targeted therapies, aiming to provide more effective and personalized treatment options for specific tumor types.

Notable figures affiliated with Tango Therapeutics include its bold leadership and passionate team, who bring extensive expertise in oncology and drug development. The company has built a robust pipeline of potential therapies and has garnered significant attention from investors in the biotech sector. Tango Therapeutics' innovative approach and commitment to patient-centered research have positioned it as a promising player in the fight against cancer, with the potential to make a substantial impact on patient outcomes.